Northland Securities reaffirmed their buy rating on shares of Evgen Pharma PLC (LON:EVG) in a research report released on Wednesday morning. Northland Securities currently has a GBX 97 ($1.29) price objective on the stock.
Shares of Evgen Pharma PLC (EVG) opened at 18.50 on Wednesday. The firm has a 50-day moving average price of GBX 17.30 and a 200 day moving average price of GBX 18.99. The stock’s market cap is GBX 13.56 million. Evgen Pharma PLC has a 12-month low of GBX 13.00 and a 12-month high of GBX 30.25.
WARNING: “Evgen Pharma PLC (EVG) Given “Buy” Rating at Northland Securities” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/10/08/evgen-pharma-plc-evg-given-buy-rating-at-northland-securities.html.
Evgen Pharma PLC Company Profile
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.